...
首页> 外文期刊>Microbial Pathogenesis >Production and characterization of monoclonal antibodies against GII.6 norovirus virus-like particles
【24h】

Production and characterization of monoclonal antibodies against GII.6 norovirus virus-like particles

机译:对GII.6诺病毒样病毒样颗粒的单克隆抗体的生产和表征

获取原文
获取原文并翻译 | 示例

摘要

In this study we generated and characterized a series of monoclonal antibodies (mAbs) against GII.6 norovirus (NoV) virus like particles (VLPs). Mice were immunized with purified GII.6 NoV VLPs and peptide-bovine serum albumin (BSA) conjugates with the peptide sequence (31 aa) derived from the trypsin cleavage region. An indirect enzyme-linked immunosorbent assay was used to identify positive cell clones during cloning and subcloning, and an in vitro VLP-histo-blood group antigens (HBGAs) binding blockade assay was used to identify mAbs with blocking ability. A total of seven mAbs comprising five (1F7, 1F11, 2B6, 2C4, and 2E10) reactive with major capsid proteins (VP1) and two (1E5 and 2B2) reactive with both VP1 proteins and the peptide were identified. mAb 1F7, 1F11, and 2B6 were identified as blocking antibodies. Sandwich ELISA indicated that all these mAbs recognized soluble GII.6 NoV VLPs. Cross-reactivities with GI.7, GII.3, and GII.4 NoV VLPs were observed in indirect and sandwich ELISA. Western blot analysis indicated that all non-blocking mAbs recognized denatured GII.6 VP1 proteins and blocking mAbs only recognized non-denatured proteins. The in vitro VLPHBGA binding blockade assay indicated that the three blocking antibodies exhibited blocking effects against GII.6 NoV VLPs, but not GI.7, GII.3, and GII.4 NoV VLPs. Epitope mapping and HBGA blocking assay indicated that mAbs targeting the predicted surface-exposed loop region did not have blocking effects, suggesting a possible important role of this region in regulating NoV-HBGA interactions. This is the first report regarding the characterization of mAbs with blocking ability against GII.6 NoV VLPs. These mAbs might be useful in facilitating our understanding of this group of viruses.
机译:在这项研究中,我们产生并表征了一种针对GII.6诺病毒(11月)病毒的一系列单克隆抗体(MAB),如颗粒(VLP)。用纯化的GII.6 Nov VLP和肽 - 牛血清白蛋白(BSA)与衍生自胰蛋白酶切割区域的肽序列(31Aa)免疫小鼠。间接酶联免疫吸附测定用于鉴定克隆和亚克隆期间的阳性细胞克隆,并且使用体外VLP-血液组抗原(HBGA)结合阻断测定法鉴定具有阻塞能力的MAb。鉴定了总共七种MAb,其与主要衣壳蛋白(VP1)和两(1E5和2B2)反应的五(1F7,1F11,2B6,2C4和2E10)与VP1蛋白和肽反应的反应性。 MAB 1F7,1F11和2B6被鉴定为阻断抗体。 Sandwich Elisa表明所有这些MAB都公认可溶性GII.6 Nov VLP。在间接和三明治ELISA中观察到具有GI.7,GII.3和GII.4的交叉反垃圾植物。 Western印迹分析表明,所有非阻塞MAB都公认变性GII.6 VP1蛋白并阻断MAb仅识别非变性蛋白质。体外VLPHBGA结合阻断测定表明,三种阻断抗体表现出对GII.6 11 vLP的阻断效应,但不是GI.7,GII.3和GII.4 Nov VLP。表位映射和HBGA阻断测定表明,靶向预测的表面暴露环区域的MAb没有阻断效应,这表明该区域在调节110-HBGA相互作用方面的可能重要作用。这是关于MAb表征的第一个报告,具有对GII.6 11 vLP的阻塞能力。这些MAB可能有助于促进我们对这群病毒的理解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号